Lonza Group Ltd news

• Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee
• Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles in Novartis finance and time working as a McKinsey consultant
• He will commence his tenure with Lonza Group on 1 December

• As part of Lonza`s continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site
• The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
• The introduction of drug product manufacturing in China will be supported by the expansio

• As part of Lonza`s continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site
• The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
• The introduction of drug product manufacturing in China will be supported by the expansio

• Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform
• The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care
• Three patients had complete responses, with another patient still under evaluation

• Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS)
• The companies share a common goal of developing and supplying advanced cell models that better reflect an in vivo environm

Ad Hoc Release Pursuant to Art. 53 Listing Rules

• Lonza launches next-generation 4D-Nucleofector® Platform, the leading non-viral cell transfection method for a wide variety of cell types – even those traditionally hard to transfect
• Modular design offers unmatched flexibility in scale and throughput with proven performance
• 4D-Nucleofector® Core Unit with user exper